Source comparison
Best Peptides for IGF-1 Elevation Research: Compound Comparison
Before selecting a peptide for IGF-1 elevation, researchers must match the pharmacokinetic profile to the study design. Short-duration studies examining acute IGF-1-dependent signaling require pulsatile compounds; longitudinal studies assessing sustained IGF-1
This comparison does not assign a generated winner or score.
- Before selecting a peptide for IGF-1 elevation, researchers must match the pharmacokinetic profile to the study design. Short-duration studies examining acute IGF-1-dependent signaling require pulsatile compounds; longitudinal studies assessing sustained IGF-1 exposure need compounds with extended half-lives. The table below compares the three most-researched compounds by onset, duration, administration route, and IGF-1 response magnitude.
- GHRP-2
- 60–90 minutes
- 4–6 hours
- 1.5–2.2× baseline (dose-dependent)
- Subcutaneous injection
- Acute signaling studies, pulsatile protocols mimicking endogenous secretion
- CJC-1295 DAC
- 24–48 hours
- 7–10 days
- 1.3–1.8× baseline (sustained)
- Longitudinal studies, sustained anabolic or neuroprotective exposure
- MK-677
- 2–4 hours (steady state after 7 days)
- 24 hours per dose
- 1.6–1.9× baseline at steady state
- Oral capsule/solution
- Compliance-sensitive studies, metabolic or body composition research
- GHRP-6
- 1.4–2.0× baseline
- Similar to GHRP-2; appetite stimulation more pronounced
- CJC-1295 (no DAC)
- 30–60 minutes
- 2–4 hours
- 1.3–1.6× baseline
- Protocols requiring flexible dosing intervals and rapid clearance
- Professional Assessment
- GHRP-2 offers the most predictable acute response for time-sensitive studies. CJC-1295 DAC simplifies dosing in longitudinal research but eliminates protocol flexibility. MK-677 is ideal when injection compliance is a barrier, though appetite effects may confound metabolic endpoints.